Management of Pyrazinamide Reactions in Tuberculosis

Immediate Management Based on Reaction Type

The American College of Chest Physicians recommends stopping rifampicin, isoniazid, and pyrazinamide immediately if liver enzymes rise to five times normal or if bilirubin increases, and continuing treatment with non-hepatotoxic drugs if the patient has infectious TB or is clinically unwell, until liver function normalizes 1, 2
Monitoring for symptoms including fever, malaise, vomiting, jaundice, or unexplained deterioration is crucial, and consideration of viral hepatitis testing to exclude coexistent viral causes is recommended 1, 2

The American Thoracic Society recommends treating with rifampicin and isoniazid for 9 months, supplemented with ethambutol for the initial 2 months, if pyrazinamide cannot be used due to confirmed adverse reaction 1
This represents a 3-month extension of therapy compared to the standard 6-month regimen, as pyrazinamide's sterilizing activity allows for treatment shortening in drug-susceptible TB 3, 4, 5

All patients receiving pyrazinamide should be monitored carefully for signs or symptoms of hepatotoxicity, with dose held or decreased if toxicity is detected, as recommended by the American Journal of Respiratory and Critical Care Medicine 3, 4, 5
Hepatic enzyme elevations are common with pyrazinamide, and serious adverse events occur in approximately 2.8% of patients receiving pyrazinamide 3, 4, 5

The Centers for Disease Control and Prevention advises against discontinuing pyrazinamide for asymptomatic hyperuricemia alone, as this is expected and clinically insignificant in most cases 3, 4, 5
Sequential reintroduction of drugs is essential to identify the specific offending agent, and combined drug preparations should not be used during reintroduction, as recommended by the World Health Organization 1, 2